NASDAQ · GEHC
Healthcare · Medical - Healthcare Information Services
$64.13
Down-$0.32 (-0.49%)
Updated Sep 20, 2026, 2:18 PM
SID Score
4.9/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
GEHC closed at $64.13 after 19 trading sessions, down 13.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $64.26 | $64.70 | $63.89 | $64.13 | 7.63M |
| Sep 17, 2026 | $63.95 | $65.255 | $62.995 | $64.445 | 4.51M |
| Sep 16, 2026 | $64.09 | $64.46 | $63.28 | $63.49 | 3.22M |
| Sep 15, 2026 | $64.25 | $64.635 | $63.61 | $64.07 | 4.26M |
| Sep 14, 2026 | $64.48 | $65.27 | $63.89 | $64.25 | 2.73M |
| Sep 11, 2026 | $64.96 | $65.40 | $63.22 | $63.93 | 3.2M |
| Sep 10, 2026 | $64.59 | $64.9468 | $63.63 | $64.24 | 3.12M |
| Sep 9, 2026 | $66.32 | $67.00 | $65.03 | $65.17 | 3.57M |
| Sep 8, 2026 | $67.95 | $68.09 | $66.74 | $66.775 | 3.12M |
| Sep 4, 2026 | $68.99 | $69.26 | $68.485 | $68.86 | 2.81M |
| Sep 3, 2026 | $71.02 | $71.36 | $68.50 | $69.72 | 3.28M |
| Sep 2, 2026 | $70.48 | $71.875 | $70.21 | $70.56 | 2.07M |
| Sep 1, 2026 | $71.25 | $71.7383 | $70.25 | $70.42 | 2.78M |
| Aug 31, 2026 | $71.30 | $71.55 | $70.2901 | $71.23 | 3.39M |
| Aug 28, 2026 | $72.82 | $73.00 | $71.5703 | $71.725 | 2M |
| Aug 27, 2026 | $72.875 | $73.40 | $72.08 | $72.48 | 2.96M |
| Aug 26, 2026 | $73.76 | $74.235 | $73.28 | $73.31 | 2.04M |
| Aug 25, 2026 | $73.87 | $74.39 | $73.15 | $73.91 | 2.01M |
| Aug 24, 2026 | $74.86 | $75.24 | $73.98 | $74.19 | 2.5M |
The latest Smart Investors Daily articles mentioning GEHC.
GEHC research
Company profile and research snapshot.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | UBS | Neutral | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Yahoo · Mar 27, 2026
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Mar 27, 2026
These companies are ready to deliver on the AI-fueled hype.
Yahoo · Mar 26, 2026
CHICAGO, March 26, 2026--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI
Benzinga · Mar 26, 2026
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GEHC.
